Vaccine Discoveries Drive India’s Biotech Industry (India)
This article was originally published in PharmAsia News
Executive Summary
India's biotechnology companies count on the vaccines end of their business to drive the rest of their work in developing therapeutics, diagnostics and other segments. The vaccines segment accounts for more than 70 percent of biotech work in the country, increasing at a rate of more than 30 percent a year, reaching the $3 billion mark by 2010. The biotechs rely heavily on public institutions to do early-stage research, such as producing cell lines, so the companies can focus on process and clinical development. That trend was begun by Shantha Biotechnic's work in developing a hepatitis B vaccine based on earlier work by the Centre for Cellular and Molecular Biology. (Click here for more
You may also be interested in...
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.
Dr Reddy’s Knocked Back On Rituximab In US
Dr Reddy’s has received a complete response letter from the US FDA, knocking back its proposed rituximab biosimilar rival to Rituxan.
Sandoz And Samsung Celebrate Stelara Rival’s EU Approval
Sandoz and Samsung Bioepis have received final European Commission approval for their partnered Pyzchiva biosimilar rival to Stelara. But with European competition on ustekinumab due to kick off in just a matter of months, further applicants are also waiting in the wings.